AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2014
Jan 24, 2014
30591_dirs_2014-01-24_767a29ab-dcb5-4236-ad8c-fcdfe9979489.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2014-01-22
Reporting Person: PARSHALL B LYNNE (Director, COO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-01-22 | Employee Stock Option (right to buy) | $7.25 | G | 5000 | Disposed | 2019-01-02 | Common Stock (5000) | Direct |
| 2014-01-22 | Employee Stock Option (right to buy) | $7.25 | G | 5000 | Acquired | 2019-01-02 | Common Stock (5000) | Indirect |
Footnotes
F1: The reporting person transferred 5,000 options to her son-in-law.
F2: Grant of 1/3/12 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/3/13. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,437 shares per year. The option shall be fully vested and exercisable on 1/3/16. The option is exercisable as to 15,875 shares on 1/22/14.